Trials / Not Yet Recruiting
Not Yet RecruitingNCT07132606
The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors
Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Yinghua Ji · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis. This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.
Detailed description
Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value. Secondary Objectives To determine correlations between serum histone succinylation levels and: Tumor types Tumor stages To statistically analyze associations of serum histone succinylation with: Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables
Conditions
Timeline
- Start date
- 2025-08-20
- Primary completion
- 2025-12-31
- Completion
- 2026-08-01
- First posted
- 2025-08-20
- Last updated
- 2025-08-20
Source: ClinicalTrials.gov record NCT07132606. Inclusion in this directory is not an endorsement.